News
TEM
80.54
-4.62%
-3.90
Tempus AI: Buy Maintained with Unchanged $95 Price Target on Data Platform and Growth Catalysts
TipRanks · 7h ago
Tempus’ Partner Blood Cancer United Launches Dare To Dream REALworld: AML, Patient-Centered Initiative Co-Founded With Rally Foundation For Childhood Cancer Research
Benzinga · 11h ago
Blood Cancer United Launches REALworld: AML to Accelerate New Treatments for Children with Blood Cancer
PR Newswire · 12h ago
Tempus AI Consensus Price Target Raised 16.31% to $89.36
NASDAQ · 22h ago
SOTERIA Precision Medicine Foundation Partners With Tempus To Provide Personalized, Data-Driven Cancer Treatment Insights, Genomic Sequencing To U.S. Military
Benzinga · 1d ago
CNH Industrial, Planet Labs, Ferguson Enterprises And Other Big Stocks Moving Higher On Monday
Benzinga · 1d ago
SOTERIA Collaborates with Tempus to Advance Precision Oncology for U.S. Military and Veterans Battling Cancer
Barchart · 1d ago
tempus AI Inc Class A call volume above normal and directionally bullish
TipRanks · 1d ago
Cathie Wood's Ark Invest buys $96M of SpaceX, adds to Nvidia and AMD; trims Broadcom
Seeking Alpha · 1d ago
Weekly Report: what happened at TEM last week (1102-1106)?
Weekly Report · 1d ago
Tempus AI: Q3 Strengthens The Platform Thesis, But Cash Returns Still Need To Catch Up
Seeking Alpha · 2d ago
Tempus AI (TEM) Reframes Valuation Following Strong Earnings And A Higher 2026 Outlook
Simply Wall St · 3d ago
Tempus AI, Inc. Class A (TEM) Gets a Hold from J.P. Morgan
TipRanks · 4d ago
Tempus AI, Inc. (NASDAQ:TEM) Just Reported And Analysts Have Been Lifting Their Price Targets
Simply Wall St · 4d ago
What Tempus AI Stock's Raised Revenue Outlook Means For Shareholders
Simply Wall St · 6d ago
Tempus AI: An Inflection Point Has Arrived (Earnings Analysis)
Seeking Alpha · 6d ago
Tempus AI (TEM) Stock Price Edges Lower After Q3 Earnings Progress
Simply Wall St · 11/04 00:47
Nancy Pelosi Isn't Running for Re-Election in 2026 Midterms: Say Goodbye to Her Stock Picks in Two Months
Benzinga · 11/03 23:55
Tempus AI Price Target Raised to $89.00/Share From $73.00 by Freedom Capital Markets
Dow Jones · 11/03 19:51
Tempus AI Is Maintained at Hold by Freedom Capital Markets
Dow Jones · 11/03 19:51
More
Webull provides a variety of real-time TEM stock news. You can receive the latest news about Tempus AI through multiple platforms. This information may help you make smarter investment decisions.
About TEM
Tempus AI, Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. It offers AI-enabled precision medicine solutions to physicians to deliver personalized patient care and, in parallel, facilitates discovery, development and delivery of optimal therapeutics. It provides three product lines: Genomics, Data and artificial intelligence applications (AI). The Genomics product line leverages its laboratories to provide next generation sequencing (NGS) diagnostics, polymerase chain reaction, profiling, molecular genotyping and other anatomic and molecular pathology testing. The data generated in its lab or ingested into its platform is structured and de-identified, prior to commercialization. Its AI Applications is focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools.